prostatic cancer
Conditions
Interventions
case series:NA
Sponsors
Zhongnan Hospital of Wuhan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Diagnosed as prostate adenocarcinoma by pathology; 2.Imaging examination including PMSA-PET and bone scan is considered as high load metastatic prostate cancer: 1 visceral metastasis and / or 4 bone metastases, and more than one of them is not in the spine or pelvis; 3.No previous anti-tumor therapy including androgen deprivation therapy; 4.ECOG score <= 2; 5.Prostate cancer tissues can be obtained for AR-V7 immunohistochemical staining; 6.Patients planning androgen deprivation therapy and docetaxel chemotherapy.
Exclusion criteria
Exclusion criteria: 1.Patients with life expectancy less than 1 year; 2.Patients with serious mental illness or other reasons that make them unable to cooperate with treatment or follow-up; 3.Patients who fail to treat according to the doctor's instructions; 4.Patients with other neoplastic diseases; 5.Prostate cancer with pathological types other than adenocarcinoma; 6.Patients with severe allergy to gonadotropin releasing hormone (GnRH) analogues; 7.Blood testosterone could not reach castration level (<= 50ng/mL) during treatment; 8.Patients receiving immunosuppressive therapy or with immune deficiency diseases; 9.Patients with severe liver function damage (Child Pugh grade C); 10.Patients with severe renal function injury who need long-term dialysis treatment; 11.Patients with severe myelosuppression and severe neutropenia; 12.Participate in other clinical studies from 30 days before enrollment to the completion of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival;Progress-free survoval; | — |
Countries
China
Contacts
Public ContactHua Xu
Zhongnan Hospital of Wuhan University
Outcome results
None listed